Ravi K Amaravadi, MD
Tara Miller Professorship of Melanoma Research and Patient Care
Attending Physician , Hospital of the University of Pennsylvania
Member, Abramson Cancer Center
Member, Institute of Translational Medicine and Therapeutics
Member, University of Pennsylvania GI Center for Molecular Studies of Digestive and Liver Diseases
Co-Director, University of Pennsylvania/Wistar Institute SPORE in Skin Cancer
Associate Director, Translational Research, Abramson Cancer Center
Tara Miller Professor of Melanoma Research and Patient Care, Abramson Cancer Center
University of Pennsylvania
Department: Medicine
Graduate Group Affiliations
Contact information
Division of Hematology Oncology
8 BRB - Room 852
Philadelphia, PA 19104
8 BRB - Room 852
Philadelphia, PA 19104
Office: 215-769-5159
Publications
Education:
BA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Permanent linkBA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Description of Research Expertise
Autophagy, Mechanisms of Cell Death, Developmental TherapeuticsDescription of Clinical Expertise
Phase I and Phase II Clinical TrialsMelanoma
Selected Publications
Wei S, Deng Y, Lee J, Lan H, Yang Z, Labrie M, Betts CB, Duan H, Tate B, Pucilowska J, Frederick D, Lawless AR, Sharova T, Yang Y, Hu W, Beasley GM, Schuchter LM, Wang X, Xu W, Yong G, Vandenberg MEG, Torigian DA, Sivagnanam S, Du K, Sugarman E, McGettigan S, Zheng C, Al-Rohil RN, Selim MA, Datto MB, López GY, Nair SK, Ashley DM, Xu X, Amaravadi RK, Karakousis GC, O'Rourke DM, Brem S, O'Malley BW, Demirkan G, Yu S, Lu Y, Camp T, Patterson JA, Wei Z, Corless C, Gabrilovich DI, Mou Y, Flaherty KT, Coussens LM, Boland G, Herlyn M, Mills G, Liu L, Zhang G.: A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma. Cell Rep Med Mar 2026.Wang H, Liu S, Sinha P, Liu F, Zhang X, Guo Y, Goncalves B, Zheng Q, Mou H, Yang J, Huang L, Miao F, Zeng T, Karakousis G, Huang AC, Mitchell T, Amaravadi R, Schuchter L, Milone M, Guo W, June C, Herlyn M, Fan Y, Xu X.: DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity. Mol Ther 34: 1465-1482, Mar 2026.
Wang SY, Turner G, Valdes-Morales KL, Hunter ER, Kim M, Tran VA, Polen K, Haynes D, Miller CJ, Etzkorn JR, Sobanko JF, Walker JL, Zhang J, Brody RM, Cannady SB, Rajasekaran K, Farwell DG, Miura JT, Karakousis GC, Lukens JR, Amaravadi RK, Schuchter LM, Mitchell TC, Higgins HW 2nd, Carey RM.: Accuracy of Sentinel Lymph Node Biopsy to Predict Nodal Metastasis in Head and Neck Merkel Cell Carcinoma. JAMA Otolaryngol Head Neck Surg 152: 313-322, Mar 2026.
Messing I, Linkowski L, Riina MD, Berger M, Baron J, Wang X, Kallan M, Hubbeling HG, Lustig RA, Dorsey JF, Kurtz G, Nagda S, Lukens JN, Flowers A, Lee JYK, Amankulor NM, Jackson C, Mohan S, Amaravadi RK, Schuchter LM, Huang AC, Mitchell TC, Alonso-Basanta M, Lebow ES.: Outcomes after SRS and ipilimumab plus nivolumab for melanoma brain metastases following prior immune checkpoint inhibitor or targeted therapy. Oncologist 31: oyag043, Mar 2026.
O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH.: Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. J Immunother Cancer 14: e012864, Jan 2026.
Wang G, Yoon D, Nandi A, Patel K, Azar T, Kim J, Han NA, Nickie A, Park S, Wang K, Yan P, Divaker S, Tabita-Martinez J, Giles L, Carberry M, Beltra JC, Painter MM, Alanio C, Amaravadi RK, Schuchter LM, Carreno BM, Linette GP, Elder DE, Brody RM, Gimotty P, Miura JT, Karakousis GC, Xu X, Mitchell TC, Huang AC.: Antigen-specific profiling identifies T-bet(+) melanoma-specific CD8(+) T cells associated with response to neoadjuvant PD-1 blockade. Cancer Cell 44: 221-234, Jan 2026.
Trifoi MD, Morales KV, Frankel D, Lin SK, Deitermann AM, Haynes D, Lubeck M, Etzkorn JR, Sobanko JF, Giordano CN, Walker JL, Zhang J, Lewis DJ, Higgins HW 2nd, Miura JT, Karakousis GC, Rajasekaran K, Cannady SB, Brody RM, Mitchell TC, Amaravadi RK, Lukens JN, Miller CJ.: Compliance with guidelines and timeliness of sentinel lymph node biopsy for Merkel cell carcinoma treated with Mohs micrographic surgery versus conventional excision at a tertiary academic center. J Am Acad Dermatol 2026.
Crissey MAS, Versace A, Bhardwaj M, Jain V, Liu S, Singh A, Beer LA, Tang HY, Villanueva J, Gimotty PA, Xu X, Amaravadi RK.: Divergent effects of acute and chronic PPT1 inhibition in melanoma. Autophagy Feb 2025.
Guo Y, Wang H, Liu S, Zhang X, Zhu X, Huang L, Zhong W, Guan L, Chen Y, Xiao M, Ou L, Yang J, Chen X, Huang AC, Mitchell T, Amaravadi R, Karakousis G, Miura J, Schuchter L, Flowers A, Zheng Q, Mou H, Gimotty P, Herlyn M, Guo W, Xu X.: Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells. Sci Adv 11: eadp9009, Jan 2025.
Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Miura JT, Karakousis GC, Xu X.: Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival. Clin Cancer Res 30: 4987-4994, Nov 2024.